Real-World Analysis of Adverse Events in Patients With Triple-Negative Breast Cancer Receiving Therapy per KEYNOTE-522
{{output}}
Purpose: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Early-stage, high-risk patients with TNBC are treated with chemotherapy and pembrolizumab per the KEYNOTE-522 regimen. This report examines ... ...
